Personal genomics

Congenica awarded second stage of European contract to develop NGS analysis workflow in oncology

Retrieved on: 
Tuesday, December 6, 2022
Health Technology, Health, Oncology, Personal genomics, NGS, Disease management, Workflow, Diagnosis, Wellcome Sanger Institute, Health, DNA sequencing, Patient, Cancer, Clinical decision support system, Degenerative disease, Standardization, Research, Precision medicine, Genomics, Integration, CE marking, Medical University of Graz, Medical imaging

Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has been awarded the second stage of a contract to develop standardised Next-Generation Sequencing (NGS) workflows in oncology for a group of seven Central European hospitals represented by the Medical University Graz.

Key Points: 
  • Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has been awarded the second stage of a contract to develop standardised Next-Generation Sequencing (NGS) workflows in oncology for a group of seven Central European hospitals represented by the Medical University Graz.
  • Alastair Johnson, Chief Professional Services Officer at Congenica, said: We are delighted to be part of this exciting project.
  • Our oncology application will offer cancer patients across Europe the utmost benefit from NGS data and rapid access to personalised healthcare.
  • Congenica was selected for the second stage of this project in October 2022 from several highly competitive applications, which were assessed in a multi-step peer-reviewed process.

Inclusivity is a Top Priority for Meeting and Event Planners, but 40% are Apathetic to the Needs of Non Native English Speaking Attendees

Retrieved on: 
Wednesday, June 8, 2022
Language, COVID, Research, Personal genomics, Marketing, CEO, Organization, Solution, Multimedia, Industry, LOS, Software as a service, Principal, Language industry, Nightclub, Risk management, Online shopping, Wordly Wise 3000

LOS ALTOS, Calif., June 8, 2022 /PRNewswire/ -- Wordly, the leading SaaS provider of AI-powered simultaneous interpretation, today announced the 2022 State of Multilingual Collaboration, a comprehensive global study by Dimensional Research. The new report provides deep insights from corporate meeting and event managers into interpretation and translation trends, challenges, and initiatives impacting multilingual collaboration.

Key Points: 
  • The new report provides deep insights from corporate meeting and event managers into interpretation and translation trends, challenges, and initiatives impacting multilingual collaboration.
  • The findings clearly illustrate that although inclusivity is of great importance to corporate meeting and event planners, 40% are apathetic to audience needs.They believe attendees will understand the language "well enough" or choose not to attend.
  • As expected a primary driver of the increase was the shift to virtual events during the pandemic.
  • As COVID restrictions lessen, 72% still expect the multilingual trend to continue over the next year.

DNA Script to Develop Next Generation of Enzymatic DNA Synthesis Printers with $2.2 Million Grant Award from the National Human Genome Research Institute of the NIH

Retrieved on: 
Tuesday, November 9, 2021
Software, Research, General Health, Hardware, Data Management, Technology, Genetics, Clinical Trials, Science, Biotechnology, Other Science, Health, View, Innovation, Personal Genome Project, Acceleration, Health, Method, RNA, National, Technology, NGS, Harvard Medical School, George Church, Research, R01, Liquid biopsy, Synthetic biology, Organic acid, Vaccine, Personal genomics, Therapy, Drug discovery, National Human Genome Research Institute, NHGRI, Library, EDS, DNA, NIH, Agriculture, Fine chemical

DNA Script aims to develop a benchtop instrument using Enzymatic DNA Synthesis (EDS) to enable for the first time in-house synthesis of high-quality long oligos in a high-multiplex format in less than a day.

Key Points: 
  • DNA Script aims to develop a benchtop instrument using Enzymatic DNA Synthesis (EDS) to enable for the first time in-house synthesis of high-quality long oligos in a high-multiplex format in less than a day.
  • The cycle time associated with chemical DNA synthesis plateaued in the 1980s; yet in less than a decade, Ive seen tremendous progress in enzymatic DNA synthesis.
  • We are confident that our next generation of enzymatic DNA synthesis printers will be successful in democratizing access to high-fidelity, low-cost nucleic acids.
  • The company has pioneered an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, and made it accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System.

Dalrada Corporation’s Pala Diagnostics Free COVID-19 Point-of-care Tests Proved Compliance for Nearly 3,000 Outdoor Festival Attendees

Retrieved on: 
Thursday, September 16, 2021
Health, Infectious Diseases, Other Science, General Health, Research, Science, Biotechnology, PCR, Engineering, FDA, Corporation, OTCQB, Technology, CEO, Health, Personal genomics, Company, Immunization, LLC, U.S. Securities and Exchange Commission, View, Annual report, Safety, Severe acute respiratory syndrome coronavirus 2, COVID-19, COVID-19 testing, Public health, EUA, Perseverance, Form 10-K, Volunteering, SEC, Pharmaceutical industry, Vaccine

Pala Diagnostics, LLC (Pala Diagnostics), a joint venture between Dalrada Health and Vivera Pharmaceuticals, Inc., is a fully operational national laboratory that processes point-of-care, EUA approved, rapid antigen testing, and lab-based PCR testing for COVID-19.

Key Points: 
  • Pala Diagnostics, LLC (Pala Diagnostics), a joint venture between Dalrada Health and Vivera Pharmaceuticals, Inc., is a fully operational national laboratory that processes point-of-care, EUA approved, rapid antigen testing, and lab-based PCR testing for COVID-19.
  • Pala Diagnostics performed both RT-PCR Tests and FDA-authorized Antigen Tests throughout the three-day Boise Pride Festival and Parade .
  • All recipients of Pala Diagnostics HIPAA compliant test results received a text message to retrieve evidence of COVID-19 testing.
  • Established in 1982, the Company has since grown its footprint to include the business divisions: Dalrada Health, Dalrada Precision, and Dalrada Technologies.

Bionano Genomics to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 4, 2021

Retrieved on: 
Wednesday, July 28, 2021
Genomics, Personal genomics, Draft:Bionano Genomics, Inc.

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.

Key Points: 
  • To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.
  • An archived version of the webcast will be available for replay in the Investors section of the Bionano website.
  • The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools.
  • Bionano provides genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs.

Dante Labs commits to ending Rare Disease Odysseys globally through Stripe2be: a patient-centric whole genome based solution tailored for rare disease patients

Retrieved on: 
Thursday, July 8, 2021
Branches of biology, Biology, Genetics, Genomics, Molecular biology, Emerging technologies, Molecular genetics, Biotechnology, Whole genome sequencing, Draft:Dante Labs, Personal genomics

Dante Labs provides affordable WGS based solutions to tens of thousands of rare disease patients worldwide, from the Marshall Islands to Brazil, from the UK to Australia

Key Points: 
  • Dante Labs provides affordable WGS based solutions to tens of thousands of rare disease patients worldwide, from the Marshall Islands to Brazil, from the UK to Australia
    8,000 rare and ultra-rare diseases affect 400 million people in the world.
  • Stripe2be is for rare disease patients in every country to access whole genome based interpretation and analysis tailored for rare diseases.
  • Stripe2be is a Dante Labs Global Whole Genome Sequencing Platform dedicated to Rare Disease Genomics.
  • Dante Labs was able to deliver by leveraging existing technology that had been developed for whole genome sequencing.

Bionano Genomics Announces Significant Progress in China with WeHealth Shanghai’s Adoption of Bionano’s Saphyr System and the Demonstration by Various Institutions of Optical Genome Mapping in Reproductive Health and Genetics

Retrieved on: 
Tuesday, July 6, 2021
Genomics, Personal genomics, Genome, Draft:Bionano Genomics, Inc.

SAN DIEGO, July 06, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced significant progress in China with the adoption of its Saphyr System for optical genome mapping (OGM) by WeHealth Shanghai, a leading provider of genome analysis services in reproductive health.

Key Points: 
  • SAN DIEGO, July 06, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced significant progress in China with the adoption of its Saphyr System for optical genome mapping (OGM) by WeHealth Shanghai, a leading provider of genome analysis services in reproductive health.
  • The adoption was announced at the Structural Variation Symposium in Shanghai, organized with support from the Shanghai Society of Genetics.
  • Multiple presentations were delivered on reproductive health, a significant need and opportunity in China with approximately 16 million births annually.
  • The China market is important in part because it represents one of the worlds largest in reproductive health and genetics.

Bionano Genomics’ Chief Medical Officer Dr. Alka Chaubey and Cancer Genomics Consortium President Dr. Yassmine Akkari to Present on Optical Genome Mapping (OGM) at the 2021 International Conference of the Board of Genetic Counseling India

Retrieved on: 
Friday, July 2, 2021
Branches of biology, Genetics, Genomics, Medical genetics, Genetic counseling, Personal genomics

SAN DIEGO, July 02, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Chief Medical Officer Dr. Alka Chaubey and current President of the Cancer Genomics Consortium Dr. Yassmine Akkari will present at the6thAnnual International Conference of theBoard of Genetic Counseling India to be held virtually from July 2nd-4th 2021.

Key Points: 
  • SAN DIEGO, July 02, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Chief Medical Officer Dr. Alka Chaubey and current President of the Cancer Genomics Consortium Dr. Yassmine Akkari will present at the6thAnnual International Conference of theBoard of Genetic Counseling India to be held virtually from July 2nd-4th 2021.
  • Dr. Akkari will present her results using OGM for the genome analysis of Acute Myelogenous Leukemia (AML), and discuss how genetic counselors can introduce OGM to patients on July 3rd at 4:10 pm IST.
  • This conference aims to promote education among genetic counselors, specialists, doctors, health care providers and students, about current topics in genetics, genomics and genetic counseling.
  • The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools.

Nucleome Therapeutics announces publication of a novel method enabling 3D genome mapping at single base pair resolution in the journal Nature

Retrieved on: 
Thursday, June 10, 2021
Branches of biology, Genomics, Genetics, Biology, Genetic mapping, Personal genomics, Human genome, DNA sequencing, Molecular biology, Biotechnology

The method, called Micro Capture-C (MCC), was invented in the laboratories of Nucleomes academic founders at the University of Oxford, and maps the 3D genome structure at unprecedented single base pair resolution.

Key Points: 
  • The method, called Micro Capture-C (MCC), was invented in the laboratories of Nucleomes academic founders at the University of Oxford, and maps the 3D genome structure at unprecedented single base pair resolution.
  • Our new method offers a significant advantage by detecting DNA interactions at base pair resolution.
  • Dr Danuta Jeziorska, Chief Executive Officer & Co-Founder of Nucleome, added: 3D genome analysis is key to understanding the largely untapped dark matter of the genome.
  • Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat disease.

Lifebit Awarded A Four-Year Contract for Hong Kong's Genome Project

Retrieved on: 
Tuesday, May 25, 2021
Branches of biology, Biology, Genetics, Genomics, Biotechnology, Genetic mapping, DNA, Molecular biology, Genome, Whole genome sequencing, Precision medicine, Personal genomics

Lifebit's precision medicine software will power Hong Kong's development of genomic medicine by supporting the Hong Kong Genome Institute to implement the first large-scale genome sequencing initiative, the Hong Kong Genome Project.

Key Points: 
  • Lifebit's precision medicine software will power Hong Kong's development of genomic medicine by supporting the Hong Kong Genome Institute to implement the first large-scale genome sequencing initiative, the Hong Kong Genome Project.
  • The Project will empower medical professionals and researchers to leverage up to 50,000 whole genomes to achieve faster diagnosis, more precise and personalised treatments and perform disease surveillance.
  • LONDON, May 25, 2021 /PRNewswire/ -- The leader in precision medicine technology, Lifebit Biotech Ltd, today announced it has been awarded a four-year contract by Hong Kong Genome Institute (HKGI) to support its implementation of the first large-scale genome sequencing initiative in Hong Kong.
  • Funded by the Hong Kong SAR Government , HKGI is tasked to take forward the implementation of the Project with the view of serving as a catalyst to establish a genome database of local population, testing infrastructure and talent pool in Hong Kong.